MedElevator
Войти в исследования BMC ophthalmology · 2026
Efficacy and safety of ultrasound cycloplasty versus ahmed glaucoma valve for neovascular glaucoma.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Shuang, Ji Shulian, Li Xiaolin, Hu Shanshan, Fu Yanjiang
Аннотация
PURPOSE: To evaluate the efficacy and safety of Ultrasound Cycloplasty (UCP) versus Ahmed Glaucoma Valve (AGV) implantation in the treatment of neovascular glaucoma.
METHODS: A total of 80 patients (80 eyes) were enrolled and assigned to receive either UCP or AGV treatment (40 eyes each). Patients were followed up for 6 months postoperatively. Intraocular pressure (IOP), number of IOP-lowering medications, pain score, visual acuity, and complications were recorded. Complete surgical success was defined as an IOP reduction of ≥ 20% from baseline and maintained between 5 and 21 mmHg, without the need for additional medications or further surgery.
RESULTS: Preoperative baseline characteristics showed no significant differences between the two groups. On postoperative day 1, the AGV group showed a greater reduction in IOP compared to the UCP group (p < 0.01). At 6 months postoperatively, the UCP group demonstrated better outcomes in terms of the IOP reduction rate (61.62% vs. 66.97%, p = 0.04) and pain score (0.13 vs. 0.43, p < 0.01) compared to the AGV group. There were no significant differences between the groups in the number of medications used or the rate of surgical success. The AGV group experienced more complications, commonly including tube blockage and plate exposure.
CONCLUSION: Both UCP and AGV are effective in reducing IOP. However, UCP resulted in more stable postoperative IOP, fewer complications, and offered better safety and patient comfort.
METHODS: A total of 80 patients (80 eyes) were enrolled and assigned to receive either UCP or AGV treatment (40 eyes each). Patients were followed up for 6 months postoperatively. Intraocular pressure (IOP), number of IOP-lowering medications, pain score, visual acuity, and complications were recorded. Complete surgical success was defined as an IOP reduction of ≥ 20% from baseline and maintained between 5 and 21 mmHg, without the need for additional medications or further surgery.
RESULTS: Preoperative baseline characteristics showed no significant differences between the two groups. On postoperative day 1, the AGV group showed a greater reduction in IOP compared to the UCP group (p < 0.01). At 6 months postoperatively, the UCP group demonstrated better outcomes in terms of the IOP reduction rate (61.62% vs. 66.97%, p = 0.04) and pain score (0.13 vs. 0.43, p < 0.01) compared to the AGV group. There were no significant differences between the groups in the number of medications used or the rate of surgical success. The AGV group experienced more complications, commonly including tube blockage and plate exposure.
CONCLUSION: Both UCP and AGV are effective in reducing IOP. However, UCP resulted in more stable postoperative IOP, fewer complications, and offered better safety and patient comfort.